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evidence-based guidelines into practical guidance
for real-world clinical practiceOsteoarthritis (OA) of the knee and hip is a major cause of
disability, ranking as the 11th highest contributor to global
disability in the 2010 Global Burden of Disease study [1]. Knee
OA affects around 4% of the global population (hip OA, 0.85%) and
the years of life lived with disability (YLDs) for hip and knee OA
was calculated at 17.1 million in 2010 [1]. With the increasing
aging population and rise in obesity worldwide, OA is forecast to
become the fourth leading cause of disability by 2020 [2], placing a
huge demand on health services to treat hip and knee OA. What
can be done to halt the progression of this disease, minimize the
impact on patient's quality of life, and restrict the burden on
healthcare resources?
The European Society for Clinical and Economic Aspects of
Osteoporosis and Osteoarthritis (ESCEO) has set out to provide
practitioners with the latest clinical and economic information,
allowing them to optimize the management of OA in their daily
practice. A ﬁrst step in this process was the publication of a
treatment algorithm for knee OA derived from analysis of the
evidence base but with emphasis on providing a practical, step-
wise approach to the management of OA patients [3].
In this issue, the ESCEO task force has revisited this guidance,
with an emphasis on real-world evidence for the clinical and
economic aspects of OA disease management. The consensus
statement included herein provides an update on selected phar-
macological interventions that are demonstrated to furnish control
of pain and other symptoms [4], improvement in function, and, in
some cases, long-term disease-modifying effects that impact on
healthcare resource utilization, such as delay in total joint replace-
ment (TJR) surgery. A signiﬁcant reduction (p = 0.024) of 57% in
the risk of TJR over 5 years has been demonstrated only following
treatment with patented crystalline glucosamine sulfate (pCGS)
(Rottapharm) [5] for 3 years [6].
Bruyère et al. [7] examine the evidence for one of the sympto-
matic slow-acting drugs in osteoarthritis (SYSADOAs), glucosamine,
which has received some variance in the level of recommendation
attributed to it, due to the multiple formulations that differ sub-
stantially in their molecular formulation and dose regimens and
hence efﬁcacy afforded. Overall, there is consensus across the guide-
lines to consider that glucosamine hydrochloride (GH) is deprived of
any beneﬁt. Conversely, in guidelines and meta-analyses that sepa-
rately assess the various formulations of glucosamine, pCGS is
consistently rated as providing a greater beneﬁt than placebo or
active comparators such as paracetamol (acetaminophen).
Real-life pharmacoeconomic studies demonstrate a long-term
reduction in the need for pain analgesia and non-steroidal anti-x.doi.org/10.1016/j.semarthrit.2015.10.014
72/& 2015 The Authors. Published by Elsevier HS Journals, Inc. This is an open
reativecommons.org/licenses/by-nc-nd/4.0/).inﬂammatory drugs (NSAIDs) with pCGS therapy over 12
months, with signiﬁcant reduction, of over 50%, in costs asso-
ciated with medication, healthcare consultations and examina-
tions (p ¼ 0.024) [6,8]. The results of the Pharmaco-
Epidemiology of GonArthroSis (PEGASus) study that sought to
determine the impact of SYSADOAs on the use of NSAIDs are
presented in this issue [8]. Over 6450 hip and knee OA patients
consulting with a general practitioner (GP) or rheumatologist in
France for a symptom ﬂare were recruited into the PEGASus
study and received a SYSADOA treatment, which included pCGS,
GH, chondroitin sulfate, avocado-soybean unsaponiﬁable, or
diacerein. Starting SYSADOA treatment, switching SYSADOAs,
continuation or discontinuation was permitted during the 2-
year follow-up. Among all SYSADOA treatments, only pCGS
achieved a signiﬁcant reduction in NSAID use of 36% (odds ratio
[OR] ¼ 0.64, 95% CI: 0.45–0.92).
Rannou et al. [9] consider the evidence for the efﬁcacy of topical
NSAIDs in hand and knee OA. In real-life studies, topical NSAIDs
demonstrate a level of efﬁcacy equivalent to that of oral NSAIDs for
knee pain during 1 year of treatment. There is some heterogeneity
between different topical NSAID formulations and the selection of
agents that demonstrate good absorption and thus bioavailability,
such as etofenamate and diclofenac, is important for good efﬁcacy.
Topical NSAIDs are not associated with the side effects attributed to
oral NSAIDs due to their lower systemic absorption.
The safety of oral NSAIDs in chronic administration has been
called into question in recent years due to the appearance of
signiﬁcant upper gastrointestinal (GI) complications and cardio-
vascular (CV) adverse events. However, NSAIDs are non-
homogenous and there are vast differences in adverse event (AE)
risk for GI and CV events. Pelletier et al. [10] examine the safety
evidence for oral NSAIDs ﬁnding that NSAIDs can provide a safe
and effective treatment for OA in real-life situations if prescribed
appropriately. Among OA patients who fail to respond to NSAIDs,
use of the sustained-release formulation of the weak opioid
tramadol, provides good pain control while minimizing AEs and
treatment discontinuations.
Maheu et al. [11] examine the evidence from real-life studies
for repeated intra-articular hyaluronic acid (IA HA) injection,
which demonstrates that IA HA can provide an improvement in
pain and function lasting up to 40 months (12 months after the
last injection). The clinical beneﬁt of IA HA may be 2-fold,
comprising mechanical viscosupplementation and the induction
of endogenous HA production, so providing lasting effect. There
is increasing evidence that the molecular weight of the HAaccess article under the CC BY-NC-ND license
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effect is different for different HA products. IA HA injections are
generally safe, although a higher occurrence of local reactions and
ﬂares has been reported with high molecular weight cross-linked
hylans.
Ultimately, a goal of OA management is to prevent or delay
development of the disease. The results of the PRevention of knee
Osteoarthritis in Overweight Females (PROOF) study presented in
this issue [12], demonstrate, for the ﬁrst time, that the daily
administration of pCGS (1500 mg/day) is able to prevent the onset
of knee OA in women at risk. The incidence of newly diagnosed OA
(measured as Z1 mm minimum joint space narrowing) among
the cohort of 204 women aged 50–60 years (with BMI Z27 kg/m2)
was reduced by 59% over 2.5 years of follow-up (OR ¼ 0.41; 95%
CI: 0.20–0.85; p ¼ 0.02). Notably, the addition of a 6-month diet
and exercise program gave no signiﬁcant beneﬁt above that
obtained with pCGS prophylaxis.
We hope that this joint effort of numerous clinicians and
scientists across Europe and North America has produced a com-
prehensive and useful supplement to facilitate the practical man-
agement of OA worldwide, and that readers will beneﬁt as much
from this supplement as we have enjoyed collaborating on it.
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